Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous fibrinogen for blood loss reduction after thoracolumbosacral fusion surgery
IRCT20250519065809N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of Fibrinogen human in perioperative bleeding, sponsored by Tehran University of Medical Sciences. Primary endpoint: Effectiveness of fibrinogen in reducing bleeding during spinal fusion surgeries. Started Jun 2025; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
perioperative bleeding
Beyond the preview
Go deeper on IRCT20250519065809N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250519065809N1.